Gilead Sciences, INC Form 4 insider transactions

Gilead Sciences Director Jacqueline K. Barton acquired restricted stock units and stock options on April 30, 2026, as detailed in a Form 4 filing.

Director Sandra Horning of Gilead Sciences acquired 1,146 restricted stock units and 4,884 stock options on April 30, 2026, with immediate vesting.

Gilead Sciences Director Ted W. Love acquired restricted stock units and stock options on April 30, 2026, as detailed in a Form 4 filing.

Javier Rodriguez, a Director at Gilead Sciences, Inc., acquired stock options and restricted stock units on April 30, 2026, as detailed in a recent SEC Form 4 filing.

Gilead Sciences Director Anthony Welters acquired restricted stock units and stock options on April 30, 2026, as detailed in a Form 4 filing.

Gilead Sciences Director Harish Manwani acquired restricted stock units and stock options on April 30, 2026, as detailed in a Form 4 filing.

Gilead Sciences Director Kelly A. Kramer acquired restricted stock units and stock options on April 30, 2026, as detailed in a Form 4 filing.

Gilead Sciences Chairman and CEO Daniel O'Day sold 10,000 shares of common stock under a pre-established Rule 10b5-1 trading plan.

Gilead Sciences CFO Andrew D. Dickinson sold 3,000 shares of common stock under a pre-arranged 10b5-1 trading plan.

Gilead Sciences Chief Commercial & Corporate Affairs Officer Johanna Mercier sold 3,000 shares of common stock.

Gilead Sciences Chairman and CEO Daniel O'Day sold 10,000 shares of common stock for approximately $1.37 million as part of a Rule 10b5-1 trading plan.

Gilead Sciences' Chief Communications Officer, Johanna Mercier, sold 3,000 shares of GILD common stock at $144.23 per share.

Gilead Sciences' Chief Financial Officer, Andrew D. Dickinson, reported the sale of 3,000 shares of common stock at $144.23 per share, executed under a pre-arranged 10b5-1 trading plan.

Gilead Sciences CFO Andrew D. Dickinson reported the vesting of restricted stock units, a new grant of RSUs and stock options, and a related tax withholding sale.

Gilead Sciences' Chief Communications and Corporate Affairs Officer, Johanna Mercier, reported the acquisition of new restricted stock units and stock options, alongside common stock transactions.

Gilead Sciences EVP Keeley M. Cain Wettan reported acquisition of common stock, restricted stock units, and non-qualified stock options, alongside a tax-related disposal of shares.

Erin Burkhart, SVP of Controllership at Gilead Sciences, Inc., was granted 2,355 restricted stock units and 5,455 non-qualified stock options.

Gilead Sciences CEO Daniel O'Day reported multiple equity transactions, including RSU vesting, stock sales for tax, and new RSU and stock option grants.

Gilead Sciences' Chief Medical Officer, Dietmar Berger, reported the acquisition of common stock and new equity incentives, alongside the sale of shares.

Gilead Sciences' Chief Financial Officer, Andrew D. Dickinson, acquired 11,090 shares of common stock through the vesting of performance share awards.

Gilead Sciences' Chief Communications and Corporate Affairs Officer, Johanna Mercier, acquired 11,090 shares of common stock through the vesting of performance share awards.

Gilead Sciences' Chief Medical Officer, Dietmar Berger, saw 8,530 performance-based common stock shares vest after meeting specific performance goals.

Gilead Sciences' EVP and General Counsel, Keeley M. Cain Wettan, acquired 470 shares of common stock through the vesting of performance share awards.

Gilead Sciences Chairman & CEO Daniel O'Day reported the vesting of performance shares and subsequent sales of common stock under a pre-arranged trading plan.

Gilead Sciences Chairman and CEO Daniel P. O'Day exercised stock options and subsequently sold an equal number of shares under a pre-arranged trading plan.

Gilead Sciences' Chief Communications and Corporate Affairs Officer, Johanna Mercier, reported the acquisition of performance-vested shares and a related disposition for tax purposes.

Gilead Sciences CFO Andrew D. Dickinson reported the vesting of performance share awards and a related tax withholding transaction.

Gilead Sciences CEO Daniel O'Day reported the acquisition of 131,675 common shares from performance awards and the disposition of 74,461 shares for tax purposes.

Gilead Sciences' Chairman and CEO, Daniel P. O'Day, reported the sale of 10,000 shares of common stock on January 28, 2026, executed under a pre-arranged Rule 10b5-1 trading plan.

Gilead Sciences CEO Daniel O'Day exercised stock options and subsequently sold shares totaling over $15.6 million, executed under a pre-arranged 10b5-1 trading plan.